Загрузка...
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
Recent major phase III trials led to the approval of immune checkpoint inhibitors (ipilimumab, pembrolizumab, and nivolumab) in metastatic malignant melanoma (MM). We aim to assess whether median progression-free survival, and 1 and 2-year overall survival (OS) rates are reliable surrogate endpoints...
Сохранить в:
| Опубликовано в: : | Medicine (Baltimore) |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wolters Kluwer Health
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4937921/ https://ncbi.nlm.nih.gov/pubmed/27368007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000003997 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|